Deutsche Bank AG acquired a new stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the 2nd quarter, Holdings Channel reports. The fund acquired 770,910 shares of the biopharmaceutical company’s stock, valued at approximately $3,932,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. SCS Capital Management LLC acquired a new stake in shares of Ardelyx in the 2nd quarter valued at about $52,000. Krilogy Financial LLC acquired a new position in shares of Ardelyx during the first quarter worth about $70,000. PVG Asset Management Corp bought a new position in shares of Ardelyx during the first quarter worth about $65,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Ardelyx by 26.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,807 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 2,491 shares in the last quarter. Finally, Richmond Investment Services LLC acquired a new stake in Ardelyx in the 1st quarter valued at approximately $72,000. 58.92% of the stock is owned by institutional investors and hedge funds.
Trending Headlines about Ardelyx
Here are the key news stories impacting Ardelyx this week:
- Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
- Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
- Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
- Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.
Analysts Set New Price Targets
Get Our Latest Stock Report on ARDX
Ardelyx Stock Up 1.1%
NASDAQ:ARDX opened at $3.78 on Wednesday. The firm has a market capitalization of $941.94 million, a price-to-earnings ratio of -17.18 and a beta of 0.70. Ardelyx, Inc. has a twelve month low of $3.72 and a twelve month high of $8.40. The stock’s 50 day moving average price is $4.97 and its two-hundred day moving average price is $5.75. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69.
Ardelyx (NASDAQ:ARDX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The company had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. During the same period in the previous year, the company posted ($0.08) EPS. The company’s quarterly revenue was up 34.3% compared to the same quarter last year. Equities research analysts expect that Ardelyx, Inc. will post -0.2 earnings per share for the current fiscal year.
Insider Activity
In other Ardelyx news, insider Eric Duane Foster sold 8,562 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $33,049.32. Following the completion of the sale, the insider owned 409,410 shares in the company, valued at $1,580,322.60. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Laura A. Williams sold 10,739 shares of Ardelyx stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $41,452.54. Following the completion of the transaction, the insider directly owned 367,456 shares of the company’s stock, valued at approximately $1,418,380.16. This trade represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 126,059 shares of company stock valued at $486,588. 5.30% of the stock is owned by corporate insiders.
About Ardelyx
Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.
Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.
Featured Stories
- Five stocks we like better than Ardelyx
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding ARDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ardelyx, Inc. (NASDAQ:ARDX – Free Report).
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
